| 2018-01-24 06:56:01|
IMMU 06:56 01/24 01/24/18
Immunomedics price target raised to $22 from $16 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Immunomedics to $22 saying his analysis suggests a 98% FDA approval probability of IMMU-132. The shares could be worth $27 on approval, Andrews tells investors in a research note. He keeps a Buy rating on Immunomedics.